Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab-Reference-Cited by-同舟云学术

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab

Published:2022-09 Issue:9 Volume:28 Page:1297-1299
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Vellas Camille,Trémeaux Pauline,Del Bello Arnaud,Latour Justine,Jeanne Nicolas,Ranger Noémie,Danet Chloé,Martin-Blondel Guillaume,Delobel Pierre,Kamar Nassim,Izopet Jacques

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference6 articles.

1. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies;Cao;Nature,2022

2. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial;Gupta;JAMA,2022

3. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies;Vellas;Clin Microbiol Infect,2022

4. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv 2021 [Epub ahead of print].

5. Antibody evasion properties of SARS-CoV-2 Omicron sublineages;Iketani;Nature,2022

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case;Microbiology Spectrum;2024-08-06

2. Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants;2024-07-08

3. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs;Cell Chemical Biology;2024-04

4. Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab;Future Virology;2024-03-23

5. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency;Cell;2024-02